<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":9421,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
AstraZeneca Pharmaceuticals LP v. Apotex Corp., 669 F.3d 1370, 101 U.S.P.Q.2d 1675 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/b2583b8c3d0acd12e2dfa40cc5832048'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/b2583b8c3d0acd12e2dfa40cc5832048'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X1Q6M57HIV82?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1Q6M57HIV82">Previous Result: <span>Baez-De-Jesus v. United States, No. 08-1...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XN85U0N?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="XN85U0N">Next Result: <span>Cohen v. CHLN, Inc., No. 2:10-cv-00514, ...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='AstraZeneca Pharmaceuticals LP v. Apotex Corp., 669 F.3d 1370, 101 U.S.P.Q.2d 1675 (Fed. Cir. 2012), Court Opinion'>
AstraZeneca Pharmaceuticals LP v. Apotex Corp., 669 F.3d 1370, 101 U.S.P.Q.2d 1675 (Fed. Cir....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>AstraZeneca Pharmaceuticals LP v. Apotex Corp., 669 F.3d 1370, 101 U.S.P.Q.2d 1675 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1H4KCA003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>AstraZeneca Pharmaceuticals LP v. Apotex Corp.</div>
<div class='displayCitation'>101 U.S.P.Q.2d 1675</div>
<div class='displayCitation'>2012 BL 30459</div>
<div class='displayCitation'>2012 BL 36466</div>
<div class='displayCitation'>669 F.3d 1370</div>
<div class='displayCitation'>bna a0d0u5r2b5</div>
<div class='displayCitation'>bna a0d0x0q6k7</div>
<div class='displayCitation'>wkffecase:25766049</div>
<div class='displayCitation'>wkffecase:25766085</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1H4KCA003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="AstraZeneca Pharmaceuticals LP v. Apotex Corp., 669 F.3d 1370, 101 U.S.P.Q.2d 1675 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="AstraZeneca Pharmaceuticals LP v. Apotex Corp." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X1H4KCA003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1H4KCA003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1H4KCA003" /><input id="title" name="title" type="hidden" value="AstraZeneca Pharmaceuticals LP v. Apotex Corp., 669 F.3d 1370, 101 U.S.P.Q.2d 1675 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="b2583b8c3d0acd12e2dfa40cc5832048" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1H4KCA003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Fb%32%35%38%33b%38c%33d%30acd%31%32e%32dfa%34%30cc%35%38%33%32%30%34%38%2Fdocument%2FX%31H%34KCA%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/bcite/X1H4KCA003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/bcite/X1H4KCA003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/bcite/X1H4KCA003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/related_content/X1H4KCA003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1688606146563";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">669 F.3d 1370</div>
<div class="cite" data-cite-type="ReporterOfDecisions">101 U.S.P.Q.2d 1675</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2011-1182, 2011-1183, 2011-1184, 2011-1185, 2011-1186,
2011-1187, 2011-1188, 2011-1189, 2011-1190.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 36466</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
ASTRAZENECA PHARMACEUTICALS LP, AstraZeneca AB, IPR Pharmaceuticals
Inc., and the Brigham and Women's Hospital, Inc., Plaintiffs-Appellants,
v. APOTEX CORP., Defendant-Appellee, and Aurobindo Pharma Limited,
Defendant-Appellee, and Cobalt Pharmaceuticals Inc. and Cobalt
Laboratories Inc., Defendants-Appellees, and Glenmark Generics
Inc. USA, Defendant-Appellee, and Mylan Pharmaceuticals Inc.,
Defendant-Appellee, and Par Pharmaceuticals, Inc.,
Defendant-Appellee, and Sun Pharmaceutical Industries, Ltd.,
Defendant-Appellee, and Teva Pharmaceuticals USA, Inc.,
Defendant-Appellee, and Torrent Pharma Inc. and Torrent Pharmaceuticals
Ltd., Defendants.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2011-1182, 2011-1183, 2011-1184, 2011-1185, 2011-1186,
2011-1187, 2011-1188, 2011-1189, 2011-1190.
</center></p>
<p><center>
February 9, 2012.
</center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442103" href="#headnote_ref_pq2-dec_442103">[1]</a> <span>Jurisdiction &mdash; Subject matter jurisdiction &mdash;
Case or controversy </span> <a href="http://www.bloomberglaw.com/document/1688606146563/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=405.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="405.0703">&#9658;405.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">Federal district court had subject matter jurisdiction over plaintiffs'
claims for patent infringement under 35 U.S.C. &sect;271(e)(2) based on defendants' existing abbreviated new drug applications, regardless of merits of plaintiffs' claims, since 28 U.S.C. &sect;1338(a) confers original jurisdiction on district courts over any civil action arising under any act of U.S. Congress relating to patents, since Congress, in enacting Section 271(e)(2), established specialized new cause of action for patent infringement, and since requirements for jurisdiction in district courts therefore are met once patent owner alleges that another's filing of ANDA infringes its patent under Section 271(e)(2), and this threshold jurisdictional determination does not depend on ultimate merits of claims.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442104" href="#headnote_ref_pq2-dec_442104">[2]</a> <span>Infringement &mdash; Tests </span> <a href="http://www.bloomberglaw.com/document/1688606146563/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.09" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.09">&#9658;120.09</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Pleadings </span> <a href="http://www.bloomberglaw.com/document/1688606146563/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.26" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.26">&#9658;410.26</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">Infringement of method patent under 35 U.S.C. &sect;271(e)(2), which defines act of infringement as filing abbreviated new drug application for &ldquo;a drug claimed in a patent or the use of which is claimed in a patent,&rdquo; requires filing of ANDA that lists at least one &ldquo;use&rdquo;
claimed in patent; in present case, plaintiffs failed to state viable claim for relief under Section 271(e)(2) against defendants whose ANDAs disclaimed all methods of using rosuvastatin calcium compounds claimed in method patents in suit, since ANDA seeking to market drug not covered by composition patent for unpatented methods of treatment cannot infringe under Section 271(e)(2), since fact that patents in suit recite uses approved by U.S. Food and Drug Administration, rather than unapproved or &ldquo;off-label&rdquo; uses, does not warrant contrary result, and since plaintiffs' policy arguments do not justify expansive interpretation of Section 271(e)(2) that would allow it to be used as &ldquo;sword&rdquo; against any ANDA seeking approval to market off-patent drug for approved use not covered by patent.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442105" href="#headnote_ref_pq2-dec_442105">[3]</a> <span>Jurisdiction &mdash; Subject matter jurisdiction &mdash;
Case or controversy </span> <a href="http://www.bloomberglaw.com/document/1688606146563/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=405.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="405.0703">&#9658;405.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">Plaintiffs failed to state ripe claim for relief under 35 U.S.C. &sect;271(e)(2)
against defendants whose abbreviated new drug applications disclaimed all methods of using rosuvastatin calcium compounds claimed in method patents in suit, since plaintiffs base their claim on allegation that U.S. Food and Drug Administration will require defendants to amend their ANDAs at some unspecified time in future to include all FDA-approved indications for rosuvastatin calcium, including those covered by patents in suit, resulting in infringement under Section 271(e)(2), since claim is not ripe for adjudication if it rests on contingent future events that may not occur as anticipated, or may not occur at all, since Section 271(e)(2)
does not encompass &ldquo;speculative&rdquo; claims for infringement, and since defendants have limited their ANDAs to unpatented methods, nothing in record indicates that FDA has required defendants to add further indications, and there is no reason to presume that FDA will do so in future.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
District of Delaware, Robert B. Kugler, J.
</p></div>
<span CLASS="page_no" data-cite="669 f 3d 1371" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1371" data-primary-citation="669 F.3d 1370">[*1371]</span> <div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="669 f 3d 1372" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1372" data-primary-citation="669 F.3d 1370">[*1372]</span> 
</p></div></div>
<div id="para2" printdualcolumn="true"><p>
  <span CLASS="page_no" data-cite="101 uspq 2d 1676" data-cite-type="ReporterOfDecisions" data-cite-pageno="1676" data-primary-citation="101 U.S.P.Q.2d 1675">[**1676]</span> Mary W. Bourke, Connolly, Bove, Lodge &amp; Hutz, LLP, of
Wilmington, DE, argued for plaintiffs-appellants. With her on
the brief was Dana K. Severance. Of counsel on the brief were
Ford F. Farabow, Jr., Finnegan, Henderson, Farabow, Garrett
&amp; Dunner, LLP, of Washington, DC; and Charles E. Lipsey,
Kenneth M. Frankel and York M. Faulkner, of Reston, VA; and
Mary K. Ferguson, of Cambridge, MA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Shane A. Brunner, Mechant &amp; Gould, P.C. of Madison, WI,
argued for defendants-appellees Aurobindo Pharma Limited and
Glenmark Generics Inc. USA. With him on the brief were Jeffrey
S. Ward and Edward J. Pardon. Of counsel on the brief was
Rachel C. Hughey, of Minneapolis, MN.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Robert B. Breisblatt and Jeremy C. Daniel, Katten Muchin
Rosenman LLP, of Chicago, IL, were on the brief for
defendant-appellee Apotex Corp.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Steven A. Maddox, Knobbe, Martens, Olson &amp; Bear, LLP, of
Washington, DC; and Payson Lemeilleur and Jared C. Bunker, of
Irvine, CA, were on the brief for defendants-appellees Cobalt
Pharmaceuticals Inc., et al.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  H. Ketto Sabharwal, Daniel E. Yonan and Dennies Varughese,
Sterne, Kessler, Goldstein &amp; Fox, PLLC, of Washington, DC,
were on the brief for defendant-appellee Glenmark Generic Inc.
USA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  William A. Rakoczy, Deanne M. Mazzochi, Joseph T. Jaros and
Eric R. Hunt, Rakoczy Molino Mazzochi Siwik, LLP, of Chicago,
IL, were on the brief for defendant-appellee Mylan
Pharmaceuticals Inc.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Nicole W. Stafford, Wilson, Sonsini, Goodrich &amp; Roisati, of
Austin, TX; and Daniel G. Brown, of New York, NY, were on the
brief for defendant-appellee Par Pharmaceutical, Inc.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  James F. Hurst, Winston &amp; Strawn LLP, of Chicago, IL, and
Charles B. Klein and John K. Hsu, of Washington, DC, were on
the brief for defendant-appellee Sun Pharmaceutical Industries,
Ltd.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Ralph J. Gabric, Jeffrey M. Nichols and Jason W. Schigelone,
Brinks Hofer Gilson &amp; Lione, of Chicago, IL, were on the
brief for defendant-appellee Teva Pharmaceuticals USA, Inc.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before RADER, Chief Judge, and LOURIE and MOORE, Circuit
Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  LOURIE, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca Pharmaceuticals LP, AstraZeneca AB, IPR
Pharmaceuticals, <span CLASS="page_no" data-cite="2012 bl 36466 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> Inc., and The Brigham and Women's Hospital,
Inc. (collectively, "AstraZeneca") appeal from the consolidated
final orders of the United States District Court for the
District of Delaware dismissing their
<span CLASS="page_no" data-cite="669 f 3d 1373" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1373" data-primary-citation="669 F.3d 1370">[*1373]</span> 
<cite>&sect; 271(e)(2)</cite> patent infringement claims against Apotex
Corp., Aurobindo Pharma Ltd., Cobalt Pharmaceuticals Inc.,
Cobalt Laboratories Inc., Glenmark Generics Inc. USA, Mylan
Pharmaceuticals Inc., Par Pharmaceuticals Inc., Sun
Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA Inc.,
Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd.
(collectively, "Appellees"). <i>Astrazeneca Pharms. LP v.</i>
<i>Apotex Corp.</i>, Nos. <cite>10-338</cite> to <cite>-346</cite> and <cite>10-584</cite>,
[<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X1Q6LG92V182?jcsearch=2010%20BL%20303012&amp;summary=yes#jcite">2010 BL 303012</a>], 2010 U.S. Dist. LEXIS 132727, <cite>2010 WL 5376310</cite> (D.Del. Dec. 22, 2010). For
the reasons indicated below, we <i>affirm.<span CLASS="page_no" data-cite="101 uspq 2d 1677" data-cite-type="ReporterOfDecisions" data-cite-pageno="1677" data-primary-citation="101 U.S.P.Q.2d 1675">[**1677]</span> </i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dispute before us involves patented methods for using the
cholesterol-lowering drug rosuvastatin calcium. Rosuvastatin
calcium is one member of a widely prescribed class of drugs
known as statins, which serve to reduce circulating cholesterol
by competitively inhibiting <cite>3-hydroxy-3-methylglutaryl-CoA</cite>
reductase, or HMG-CoA reductase, a key enzyme in the
cholesterol biosynthesis pathway. AstraZeneca markets
rosuvastatin calcium under the brand name CRESTOR&reg; and
holds the rights to three related patents relevant to this
appeal. U.S. Patent RE37.314 ("the &prime;314 patent") claims
rosuvastatin compounds and pharmaceutical compositions
containing such compounds. U.S. Patent 6,858,618 ("the
&prime;618 patent") claims methods of using rosuvastatin
compounds to treat heterozygous familial hypercholesterolemia
("HeFH"), a genetic condition characterized by impaired
cholesterol metabolism and clinically elevated blood
cholesterol, and U.S. Patent 7,030,152 ("the &prime;152
patent") claims methods of using rosuvastatin compounds to
lower the cardiovascular disease risk for individuals who have
normal cholesterol levels but demonstrate elevated circulating
C-reactive protein ("CRP"), another risk factor associated with
various cardiovascular disorders. The &prime;314 composition
patent expires in 2016, while the &prime;618 and &prime;152
method of use patents expire in 2021 and 2018,
respectively.<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca filed a New Drug Application ("NDA") to market
rosuvastatin calcium and obtained approval from the U.S. Food
and Drug Administration ("FDA") on August 12, 2003. As required
by the Drug Price Competition and Patent Term Restoration Act
of 1984 (popularly known as the Hatch-Waxman Act, hereinafter
"the Act"), AstraZeneca notified the FDA of all patents that it
believed could be infringed by the unlicensed manufacture, use,
or sale of rosuvastatin calcium to be published in the FDA's
<i>Approved Drug Products with Therapeutic Equivalence</i>
<i>Evaluations</i> (known as "the Orange Book"). <i>See</i>
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1). Among those patents, AstraZeneca listed
the &prime;314, &prime;618, and &prime;152 patents. The
approved NDA and AstraZeneca's corresponding CRESTOR&reg;
labeling cover several indications for using rosuvastatin
calcium, including treatment of HeFH in pediatric patients and
preventative use in high-risk patients with elevated CRP. J.A.
152. While these indications may fall under AstraZeneca's
method patents, the FDA also approved rosuvastatin calcium for
<span CLASS="page_no" data-cite="2012 bl 36466 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> treating homozygous familial hypercholesterolemia ("HoFH") and
hypertriglyceridemia &mdash; uses not claimed by either of the
&prime;618 or &prime;152 patents. Thus, the FDA approved
rosuvastatin calcium for a number of different treatment
indications, some of which may be protected by AstraZeneca's
&prime;618 and &prime;152 patents, <i>i.e.</i>, the HeFH and
elevated CRP indications, as well as others not subject to any
such
<span CLASS="page_no" data-cite="669 f 3d 1374" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1374" data-primary-citation="669 F.3d 1370">[*1374]</span> 
patent rights, <i>e.g.</i>, treatment of HoFH and
hypertriglyceridemia.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellees are generic pharmaceutical manufacturers that filed
Abbreviated New Drug Applications ("ANDAs") with the FDA
seeking to market generic rosuvastatin calcium. As set forth
at <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(i)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(i), the Act only allows ANDA
filers to obtain approval for marketing drugs for uses that
have been approved under a preexisting NDA. In this case,
Appellees further restricted their ANDAs, requesting approval
to offer their generic rosuvastatin formulations for treating
only HoFH and hypertriglyceridemia while omitting or "carving
out" patented indications directed toward HeFH and elevated
CRP. Mylan's proposed labeling is representative:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                          <b>INDICATIONS AND USAGE</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Rosuvastatin calcium tablets are an HMG-CoA reductase inhibitor
indicated for:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  &bull; patients with hypertriglyeridemia as an adjunct
  to diet (1.2)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  &bull; patients with homozygous familial
  hypercholesterolemia (HoFH) to reduce LDL-C, total-C,
  and ApoB (1.4)
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 284. It appears undisputed that none of Appellees' ANDAs
sought approval to market rosuvastatin calcium specifically for
the HeFH or high-CRP indications disclosed in the &prime;618
and &prime;152 patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellees' ANDAs also addressed each rosuvastatin-related
patent listed in the Orange Book. The Act requires each ANDA
applicant to certify that (1) the Orange Book contains no
patent information relevant to their ANDA ("Paragraph I
certification"), (2) the listed patents have expired
("Paragraph II certification"), (3) the applicant will not
enter the market until the listed patents expire ("<span CLASS="page_no" data-cite="101 uspq 2d 1678" data-cite-type="ReporterOfDecisions" data-cite-pageno="1678" data-primary-citation="101 U.S.P.Q.2d 1675">[**1678]</span> Paragraph
III certification"), or (4) the applicant believes that the
listed patents are invalid or will not be infringed by the
applicant's generic compositions ("Paragraph IV
certification"). <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(I)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(vii)(I)-<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(IV)&amp;summary=yes#jcite">(IV)</a>
(2006). The Act specifies that filing an ANDA containing a
Paragraph IV certification constitutes an act of infringement.
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2) (2006); <i>Glaxo, Inc. v. Novopharm,</i>
<i>Ltd.</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X31Q33?jcsearch=110%20f%203d%201562&amp;summary=yes#jcite">110 F.3d 1562</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X31Q33?jcsearch=110%20f%203d%201562&amp;summary=yes#jcite">1568-69</a> (Fed. Cir. 1997). Where the
Orange Book lists a method of use patent that "does not claim a
use for which the applicant is seeking approval," an applicant
may instead submit a statement under
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(viii)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(viii) averring that the ANDA excludes all uses
claimed in the patent ("Section viii statement").
<i>Warner-Lambert Co. v. Apotex Corp.</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d 1348</a>,
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">1360-61</a> (Fed. Cir. 2003).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, Appellees filed Paragraph IV certifications with
regard to the &prime;314 composition patent, but, having only
sought approval for unpatented methods of using generic
rosuvastatin calcium for treating HoFH and hypertriglyeridemia,
they submitted Section viii statements regarding the &prime;618
and &prime;152 method of use patents.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> Appellees notified
AstraZeneca of their ANDA filings in late 2007 as required
under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(B)(ii)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(B)(ii).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In December <span CLASS="page_no" data-cite="2012 bl 36466 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> 2007, AstraZeneca responded by suing Appellees for
infringement of the &prime;314 composition patent under
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. After a bench trial, the district court ruled on
June 29, 2010, in favor of AstraZeneca on infringement,
validity, and enforceability of the &prime;314 patent,
enjoining Appellees from making, using, or selling rosuvastatin
calcium until the &prime;314
<span CLASS="page_no" data-cite="669 f 3d 1375" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1375" data-primary-citation="669 F.3d 1370">[*1375]</span> 
patent expires in 2016. Appellees have separately appealed
that decision. <i>In re Rosuvastatin Calcium Patent</i>
<i>Litig.</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X1Q6LCAJE8O2?jcsearch=719%20f%20supp%202d%20388&amp;summary=yes#jcite">719 F.Supp.2d 388</a> (D.Del. 2010), <i>appeal</i>
<i>docketed</i>, Nos. <cite>10-1460</cite> to <cite>-1473</cite> (Fed. Cir. Aug. 13, 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the &prime;314 infringement matter remained pending
before the district court, AstraZeneca brought a second
<cite>&sect; 271(e)(2)</cite> action against Appellees in April 2010 that
ultimately gave rise to this appeal.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> AstraZeneca alleged
that Appellees' ANDA filings infringed and would cause
infringement of the &prime;618 and 152 method patents, even
though Appellees had not requested approval for any patented
indications and had filed Section viii statements to that
effect. In particular, AstraZeneca's complaints stated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  25. On information and belief, the FDA will require
  the label for the [Appellees'] Rosuvastatin Calcium
  Tablets to include information relating to the use to
  treat pediatric patients 10 to 17 years of age having
  HeFH.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  . . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  27. On information and belief, the labeling associated
  with the [Appellees'] Rosuvastatin Calcium Tablets
  causes [their ANDAs] to be an application for a drug
  the use of which is claimed in the &prime;618 patent
  in violation of <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  . . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  29. On information and belief, the [Appellees']
  Rosuvastatin Calcium Tablets, if approved by the FDA,
  will be prescribed and administered to human patients
  to treat HeFH, which uses will constitute direct
  infringement of the &prime;618 patent. . . . On
  information and belief, [Appellees] will actively
  induce, encourage, and aid and abet this prescription
  and administration, with knowledge and specific intent
  that these uses will be in contravention of
  [AstraZeneca's] rights under the &prime;618
  patent.<a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 164-65. Each complaint also included analogous counts
alleging infringement of the &prime;152 patent. <i>E.g.</i>,
J.A. 166-67, &para;&para; 39-43. In short, AstraZeneca alleged that:
(1) Appellees' ANDAs, as filed, violated &sect; 271(e)(2) as
"application[s] for a drug the use of which is claimed" in the
&prime;618 and 152 patents; (2) if approved by the FDA,
Appellees' proposed activities will induce infringement of the
&prime;618 and 152 patents; and (3) the FDA will require
Appellees to make labeling amendments explicitly incorporating
the indications covered by the &prime;618 and 152 patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellees moved to dismiss on three grounds. First, Appellees
argued that the district court lacked subject matter
jurisdiction over AstraZeneca's claims because <span CLASS="page_no" data-cite="101 uspq 2d 1679" data-cite-type="ReporterOfDecisions" data-cite-pageno="1679" data-primary-citation="101 U.S.P.Q.2d 1675">[**1679]</span> &sect; 271(e)(2)
creates a case or controversy only if the accused ANDA contains
a Paragraph IV certification, but Appellees instead filed
Section viii statements concerning the asserted method patents.
In addition, Appellees argued that the infringement claims were
unripe because AstraZeneca alleged that the FDA might, at some
undetermined point in the future, require that Appellees amend
their ANDAs to include the patented <span CLASS="page_no" data-cite="2012 bl 36466 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> indications. Finally,
Appellees argued that, even if the court could exercise
jurisdiction, the complaints failed to state a claim under
&sect; 271(e)(2) because AstraZeneca had not alleged and could
not allege that Appellees' ANDAs included Paragraph IV
certifications
<span CLASS="page_no" data-cite="669 f 3d 1376" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1376" data-primary-citation="669 F.3d 1370">[*1376]</span> 
or sought approval to market rosuvastatin calcium for uses
claimed in the &prime;618 or &prime;152 patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court dismissed AstraZeneca's infringement claims,
ruling that it lacked jurisdiction because AstraZeneca had not
presented a valid &sect; 271(e)(2) claim based on Appellees'
ANDA filings. <i>AstraZeneca</i>, <cite>2010 WL 5376310</cite>, at *10-14.
The court also held that AstraZeneca's claims were unripe to
the extent that they relied on presumptive future labeling
amendment. <i>Id.</i> at *15.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca now appeals, and we have jurisdiction under
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review <i>de novo</i> a district court's decision to
dismiss for lack of subject matter jurisdiction, and we review
any underlying factual findings for clear error.
<i>Hewlett-Packard Co. v. Acceleron LLC</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X1C73V2003?jcsearch=587%20f%203d%201358&amp;summary=yes#jcite">587 F.3d 1358</a>,
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X1C73V2003?jcsearch=587%20f%203d%201358&amp;summary=yes#jcite">1361</a> (Fed. Cir. 2009). Like the district court, we test the
sufficiency of a complaint as a matter of law, accepting as
true all non-conclusory allegations of fact. <i>Bradley v.</i>
<i>Chiron Corp.</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XN5ABBQNB5G0?jcsearch=136%20f%203d%201317&amp;summary=yes#jcite">136 F.3d 1317</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XN5ABBQNB5G0?jcsearch=136%20f%203d%201317&amp;summary=yes#jcite">1321-22</a> (Fed. Cir. 1998). We
also review statutory interpretation, which is a question of
law, without deference. <i>Waymark Corp. v. Porta Sys.</i>
<i>Corp.</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X4MSFO?jcsearch=245%20f%203d%201364&amp;summary=yes#jcite">245 F.3d 1364</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X4MSFO?jcsearch=245%20f%203d%201364&amp;summary=yes#jcite">1366</a> (Fed. Cir. 2001).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As described, AstraZeneca's complaints advanced two basic
theories of patent infringement under &sect; 271(e)(2). First,
AstraZeneca alleged that, as filed, Appellees' ANDAs infringe
the &prime;618 and &prime;152 method patents because their
approval would result in unlicensed sales of a drug having
FDA-approved, patent-protected uses, inevitably infringing
AstraZeneca's method patents contrary to the plain language and
legislative aims of &sect; 271(e)(2). AstraZeneca also asserted
that the FDA would ultimately block Appellees' formal efforts
to carve out the patented indications by requiring amendments
extending their ANDAs to include <i>all</i> approved
indications for rosuvastatin calcium &mdash; including those
covered by the &prime;618 and &prime;152 patents. The district
court dismissed these claims on separate grounds, and we
address each in turn.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                      <i>A. Appellees' ANDAs as Filed</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court dismissed AstraZeneca's primary
&sect; 271(e)(2) infringement claims for lack of subject matter
jurisdiction. The court reasoned that &sect; 271(e)(2) creates
in the ANDA context a limited, technical, and artificial cause
of action where none would otherwise exist, so that in such
cases "a district court's jurisdiction turns on whether a
plaintiff asserts a valid claim under Section 271(e)(2). . . .
[I]n the absence of a Section 271(e)(2) claim, there is no
justiciable case or controversy between the parties."
<i>Astrazeneca</i>, <cite>2010 WL 5376310</cite>, at *11. Concluding that
AstraZeneca had failed to state a valid <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> claim
because Appellees' ANDAs excluded all methods of using
rosuvastatin calcium claimed in the asserted patents, the
district court dismissed AstraZeneca's claims pursuant to
Fed.R.Civ.P. <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">12</a>(b)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca protests that, by alleging patent infringement
under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>, it has asserted a claim for relief
arising under federal patent <span CLASS="page_no" data-cite="2012 bl 36466 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> law and has thus met the basic
jurisdictional requirements specified in <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEIMUO003?jcsearch=28%20usc%201331&amp;summary=yes#jcite">28 U.S.C. &sect;&sect; 1331</a>
and <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEIMV6003?jcsearch=28%20U.S.C.%20%201338(a)&amp;summary=yes#jcite">1338</a>(a). In addition, AstraZeneca argues that
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> is not a jurisdiction-conferring statute and that the
district court improperly conflated its jurisdictional analysis
with scrutiny of the claims <i>on</i> their merits. Appellees
defend the district court's dismissal as properly premised on
jurisdictional grounds.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442103" href="#headnote_pq2-dec_442103">[1]</a> As a preliminary matter, we agree with AstraZeneca that its
infringement claims based on Appellees' existing ANDAs were
<span CLASS="page_no" data-cite="669 f 3d 1377" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1377" data-primary-citation="669 F.3d 1370">[*1377]</span> 
within the district court's jurisdiction. The district
courts have original jurisdiction over any civil action arising
under any Act of Congress relating to patents.
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEIMV6003?jcsearch=28%20usc%201338&amp;summary=yes#jcite">28 U.S.C. &sect; 1338</a>(a). The Supreme Court has described <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> as
creating "a highly artificial act of infringement" triggered
upon submission of an ANDA containing an erroneous Paragraph IV
certification. <i>Eli Lilly &amp; Co. v. Medtronic, Inc.</i>,
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">496 U.S. 661</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X5CBTS?jcsearch=496%20us%20661&amp;summary=yes#jcite">678</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/1?citation=110%20supreme%20court%202683&amp;summary=yes#jcite">110 S.Ct. 2683</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X5CBTS?jcsearch=110%20l%20ed%202d%20605&amp;summary=yes#jcite">110 L.Ed.2d 605</a> (1990). We
have further explained that &sect; 271(e)(2) provided a new
cause of action so that courts could promptly resolve
infringement and validity disputes before the ANDA <span CLASS="page_no" data-cite="101 uspq 2d 1680" data-cite-type="ReporterOfDecisions" data-cite-pageno="1680" data-primary-citation="101 U.S.P.Q.2d 1675">[**1680]</span> applicant
had engaged in the traditional statutorily defined acts of
infringement. <i>Glaxo</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X31Q33?jcsearch=110%20f%203d%201562&amp;summary=yes#jcite">110 F.3d at 1569</a>. By enacting
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>, Congress thus established a specialized new
cause of action for patent infringement. When patentees pursue
this route, their claims necessarily arise under an Act of
Congress relating to patents. In short, "[o]nce Congress
creates an act of infringement, jurisdiction in the district
courts is proper under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEIMV6003?jcsearch=28%20U.S.C.%20%201338(a)&amp;summary=yes#jcite">28 U.S.C. &sect; 1338</a>(a)." <i>Allergan,</i>
<i>Inc. v. Alcon Labs., Inc.</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X6CGLT?jcsearch=324%20f%203d%201322&amp;summary=yes#jcite">324 F.3d 1322</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X6CGLT?jcsearch=324%20f%203d%201322&amp;summary=yes#jcite">1330</a> (Fed. Cir.
2003).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Allergan</i>, we addressed a similar jurisdictional
challenge to an infringement suit brought under
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. There, as here, the plaintiff held method patents
directed toward certain uses of a drug, competitors filed ANDAs
seeking to market the drug for other uses, and the plaintiff
brought suit claiming that the ANDAs infringed its method of
use patents under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. <i></i><a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X6CGLT?jcsearch=324%20F.3d%201322&amp;summary=yes#jcite">Id. at 1328</a>. The
defendant competitors argued that <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> did not
provide jurisdiction because their ANDAs sought approval for
uses not covered by the asserted patents, but we held that
"<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">section 271(e)(2)</a> makes it possible for the district court to
exercise its <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEIMV6003?jcsearch=28%20U.S.C.%20%201338(a)&amp;summary=yes#jcite">section 1338(a)</a> jurisdiction in the situation in
which an ANDA has been filed." <i></i><a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X6CGLT?jcsearch=324%20F.3d%201322&amp;summary=yes#jcite">Id. at 1330</a>. In other
words, the requirements for jurisdiction in the district courts
are met once a patent owner alleges that another's filing of an
ANDA infringes its patent under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>, and this
threshold jurisdictional determination does not depend on the
ultimate merits of the claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Consistent with <i>Allergan</i>, we conclude that the
district court erred in holding that its jurisdiction hinged on
whether AstraZeneca asserted a "valid" claim under
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. AstraZeneca alleged that the Appellees' ANDA filings
infringed its listed patents under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>, and nothing
more was required to establish the district court's subject
matter jurisdiction pursuant to <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEIMV6003?jcsearch=28%20U.S.C.%20%201338(a)&amp;summary=yes#jcite">&sect; 1338(a)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442104" href="#headnote_pq2-dec_442104">[2]</a> While the district court erroneously concluded that it lacked
subject matter jurisdiction over AstraZeneca's claims, its
judgment of dismissal was nevertheless correct, for we agree
with the district court's underlying determination that
AstraZeneca <span CLASS="page_no" data-cite="2012 bl 36466 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> failed to state a viable claim for relief under
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. <i>See Samish Indian Nation v. United</i>
<i>States</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X12MQQQ003?jcsearch=419%20f%203d%201355&amp;summary=yes#jcite">419 F.3d 1355</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X12MQQQ003?jcsearch=419%20f%203d%201355&amp;summary=yes#jcite">1364</a> (Fed. Cir. 2005) ("The court can
affirm the trial court on any basis in the record.");
<i>Susquehanna Valley Alliance v. Three Mile Island Nuclear</i>
<i>Reactor</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XABELC?jcsearch=619%20f%202d%20231&amp;summary=yes#jcite">619 F.2d 231</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XABELC?jcsearch=619%20f%202d%20231&amp;summary=yes#jcite">239</a> (3d Cir. 1980) ("Returning that
Count to the district court for the entry of a dismissal under
Fed.R.Civ.P. <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(6)&amp;summary=yes#jcite">12</a>(b)(6), rather than under Fed.R.Civ.P. <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">12</a>(b)(1),
would be a futile exercise.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We are guided in this conclusion by the language of
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> itself and by our decision in
<i>Warner-Lambert.</i> <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">Section 271(e)(2)</a> provides as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It shall be an act of infringement to submit &mdash;
  (A) an application [<i>i.e.</i>, an ANDA] under
  <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">section 505(j)</a> of the Federal Food, Drug, and Cosmetic
  Act [codified at <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)] for a drug
  claimed in a patent or <i>the use of which</i> is
  claimed in a patent . . . if the purpose of such
  submission is to obtain approval
<span CLASS="page_no" data-cite="669 f 3d 1378" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1378" data-primary-citation="669 F.3d 1370">[*1378]</span> 
  under such Act to engage in the commercial
  manufacture, use, or sale of a drug . . . claimed in a
  patent or <i>the use of which</i> is claimed in a
  patent before the expiration of such patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2) (emphases added). In
<i>Warner-Lambert</i>, we construed the term "the use" as
used in &sect; 271(e)(2)(A) to mean "the use listed in the ANDA"
based on our evaluation of the statutory language, its context
within the Act, and the legislative history behind its
enactment. <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/1?citation=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1356-60</a>. Accordingly, we held that it is
not necessarily an act of infringement under &sect; 271(e)(2) to
submit an ANDA for a drug if just <i>any</i> use of that drug
is claimed in a patent; rather, infringement of method claims
under &sect; 271(e)(2) requires filing an ANDA wherein at least
one "use" listed in the ANDA is claimed in a patent.
<i>Id.</i> at 1358-59.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Relying on <i>Warner-Lambert</i>, the district court
determined that AstraZeneca had not stated a claim under
&sect; 271(e)(2) as a predicate to its decision to dismiss for lack of
jurisdiction. The district court held that
<i>Warner-Lambert</i> defined the boundaries of
&sect; 271(e)(2) claims by establishing that "ANDA applicants could
carve out patented uses from their ANDAs even if those uses
were FDA-approved." <i>Astrazeneca</i>, <cite>2010 WL 5376310</cite>, at
*13. The district court therefore concluded that there can be
no cause of action for infringement of a method of use claim
under &sect; 271(e)(2) unless the accused ANDA actually seeks
approval for a patented indication. <i>Id.</i> at *14.
Because Appellees had excluded any patented treatment
indications from their ANDAs, <a HREF="#fn500" name="fnref_fn500">[fn5]</a> the <span CLASS="page_no" data-cite="101 uspq 2d 1681" data-cite-type="ReporterOfDecisions" data-cite-pageno="1681" data-primary-citation="101 U.S.P.Q.2d 1675">[**1681]</span> district court concluded
that AstraZeneca "[does] not have a claim under
Section 271(e)(2)." <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca first asserts that the district court employed an
unduly narrow reading of &sect; 271(e)(2). It claims that the
"plain and unambiguous" language of &sect; 271(e)(2) supports
its infringement claims, quoting the statute "in relevant part"
as follows: "It shall be an act of infringement to submit
&mdash; (A) an application under section 505(j) of the Federal
Food, Drug, and Cosmetic Act [<i>i.e.</i>, an ANDA] . . . for
a drug . . . the use of which is claimed in a patent. . . ."
Non-Confidential Br. for Plaintiffs-Appellants at 23
(formatting in original). AstraZeneca thus argues that it
stated cognizable claims under &sect; 271(e)(2) by alleging that
Appellees filed ANDAs for "a drug," rosuvastatin calcium, "the
use of which is claimed in a patent," such as the &prime;618
and &prime;152 patents. However, AstraZeneca's selective
quotation <span CLASS="page_no" data-cite="2012 bl 36466 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> omits key language from &sect; 271(e)(2), condensing
the statutory bases for liability to filing an ANDA for "a drug
. . . the use of which is claimed in a patent," rather than
using the actual language of the statute reading "a drug
<i>claimed in a patent or</i> the use of which is claimed in
a patent." <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A) (emphasis added). In
fact, AstraZeneca's argument stems from the same misleading
"abridged quotation" of <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> proffered by the
plaintiff in
<span CLASS="page_no" data-cite="669 f 3d 1379" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1379" data-primary-citation="669 F.3d 1370">[*1379]</span> 
<i>Warner-Lambert. See</i> <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1355</a>. Then as now,
we rejected this parsing of the statute because it "eviscerated
an important part of the statutory provision by conflating the
first and second clauses of <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)(A)</a>," <i><a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20F.3d%201348&amp;summary=yes#jcite">id</a>.</i>,
and we again reject the contention that filing an ANDA for a
drug having any patented use automatically constitutes
infringement under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. As we held in
<i>Warner-Lambert</i>, a patented method of using a drug can
only be infringed under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> by filing an ANDA that
seeks approval to market the drug for that use. <i></i><a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20F.3d%201348&amp;summary=yes#jcite">Id.
at 1358</a>-<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=59&amp;summary=yes#jcite">59</a>. Thus, an ANDA seeking to market a drug not covered by
a composition patent for unpatented methods of treatment cannot
infringe under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. AstraZeneca has not alleged,
nor could it allege, that Appellees' ANDAs seek FDA approval
for uses of rosuvastatin calcium covered by the &prime;618 or
&prime;152 patents as would be required to state a viable
&sect; 271(e)(2) claim.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca attempts to distinguish <i>Warner-Lambert</i> on
its facts, pointing out that the patent asserted in that case
claimed an unapproved or "off-label" use, while AstraZeneca's
&prime;618 and &prime;152 patents recite FDA-approved uses for
rosuvastatin calcium. AstraZeneca urges that a generic
manufacturer's formal carve-out has less significance where a
patent holder has expended the considerable effort and
resources required to obtain FDA approval for its patented
method of use. In such cases, according to AstraZeneca, not
only has the patent holder engaged in precisely the type of
innovative activity that the Act sought to encourage, but such
patentees &mdash; claiming FDA-approved therapeutic
applications already familiar in the market &mdash; also face
more compelling infringement risks than a patentee claiming
unapproved uses for a drug as in <i>Warner-Lambert.</i>
AstraZeneca therefore argues that <i>Warner-Lambert</i> is
inapposite and does not compel us to preclude all
&sect; 271(e)(2) claims based on method of use patents where the ANDA
does not expressly recite a patented method.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  These arguments are unavailing. Although AstraZeneca is correct
that the patent at issue in <i>Warner-Lambert</i> claimed an
off-label use for a drug, that distinction is irrelevant for
purposes of &sect; 271(e)(2). When considering allegations that
an ANDA filing infringes a patented method, &sect; 271(e)(2)
directs our analysis to the scope of approval sought in the
ANDA &mdash; the statute defines the infringing act as filing
an ANDA for "a drug claimed in a patent or the use of which is
claimed in a patent." <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A). And while
generic applicants cannot obtain approval for uses beyond those
already approved by the FDA, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(i)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(i),
nothing in the Act requires that an ANDA must encompass
<i>every</i> approved indication. As we explained in
<i>Warner-Lambert</i>:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Congress recognized that a single drug <span CLASS="page_no" data-cite="2012 bl 36466 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> could have more
  than one indication and yet that the ANDA applicant
  could seek approval for less than all of those
  indications. Congress clearly contemplated that the
  FDA could grant approval . . . of an ANDA, <span CLASS="page_no" data-cite="101 uspq 2d 1682" data-cite-type="ReporterOfDecisions" data-cite-pageno="1682" data-primary-citation="101 U.S.P.Q.2d 1675">[**1682]</span> seeking to
  market a drug for a single indication even when other
  indications were known or even approved. . . . [T]he
  applicant needs only to certify [under Paragraph IV]
  with respect to use patents that claim an indication
  <i>for which the applicant is seeking approval to</i>
  <i>market the drug.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Warner-Lambert</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1360</a>. In other words, the
Act allows generic manufacturers to limit the scope of
regulatory approval they seek &mdash; and thereby forego
Paragraph IV certification and a <cite>&sect; 271(e)(2)</cite> infringement
suit &mdash; by excluding patented indications from their
ANDAs. We see no reason why those provisions would, on the one
hand, foreclose <cite>&sect; 271(e)(2)</cite> liability if an ANDA excludes a
<span CLASS="page_no" data-cite="669 f 3d 1380" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1380" data-primary-citation="669 F.3d 1370">[*1380]</span> 
patented but <i>unapproved</i> use as in
<i>Warner-Lambert</i>, and yet, under otherwise identical
circumstances, allow AstraZeneca to pursue <cite>&sect; 271(e)(2)</cite>
claims based on the patented, <i>FDA-approved</i> uses that
were carved out in this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca also argues that following <i>Warner-Lambert</i>
would enable generic manufacturers to unilaterally insulate
themselves from infringement under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> by filing
ANDAs with improper or misleading Section viii statements. But
AstraZeneca does not allege or argue that Appellees'
Section viii statements were erroneous, nor would an unfounded
Section viii statement necessarily immunize an ANDA that actually seeks
approval for a patented treatment or necessarily leave the
patentee without recourse under <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>. We do not
opine on such a fact situation not before us.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AstraZeneca also argues that Section viii statements and
restricted generic labeling ignore market realities because
even if a generic drug is formally approved only for unpatented
uses, pharmacists and doctors will nonetheless substitute the
generic for all indications once it becomes available. We find
this argument unpersuasive. First, AstraZeneca's position
would, in practice, vitiate <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(viii)&amp;summary=yes#jcite">&sect; 355(j)(2)(A)(viii)</a> by
enabling <cite>&sect; 271(e)(2)</cite> infringement claims despite the fact
that Appellees' Section viii statements and corresponding
proposed labeling explicitly and undisputedly carve out all
patented indications for rosuvastatin calcium. Moreover, if
accepted, these speculative arguments would allow a pioneer
drug manufacturer to maintain de facto indefinite exclusivity
over a pharmaceutical compound by obtaining serial patents for
approved methods of using the compound and then wielding
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> "as a sword against any competitor's ANDA seeking
approval to market an off-patent drug for an approved use not
covered by the patent. Generic manufacturers would effectively
be barred altogether from entering the market."
<i>Warner-Lambert</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1359</a>. We cannot agree with
this expansive view of <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>, which is contrary to
the statutory scheme. If an off-patent drug is being used for
an unpatented use, that is activity beyond the scope of
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(a)</a>. So is filing an ANDA seeking to market an unpatented
drug for an unpatented use beyond the scope of <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In summary, the conclusions <span CLASS="page_no" data-cite="2012 bl 36466 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> set forth in
<i>Warner-Lambert</i> also govern the facts of this case.
Because Appellees have submitted ANDAs seeking approval to
market rosuvastatin calcium for uses that are not subject to
AstraZeneca's &prime;618 and &prime;152 method of use patents,
AstraZeneca does not state a claim for infringement of these
patents under &sect; 271(e)(2).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
              <i>B. AstraZeneca's Proposed Labeling Amendments</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition, AstraZeneca also alleged that "the FDA <i>mil</i>
<i>require</i> the label for [Appellees'] Rosuvastatin Calcium
Tablets to include information relating to" the uses claimed in
the &prime;618 and &prime;152 patents. <i>E.g.</i>, J.A. 164
(emphasis added). In effect, AstraZeneca alleged that the FDA
will require Appellees to amend their ANDAs at some unspecified
point in the future to include all FDA-approved indications for
rosuvastatin calcium, including those covered by the &prime;618
and &prime;152 patents, resulting in infringement under
&sect; 271(e)(2). The district court dismissed those claims under
Fed.R.Civ.P. <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X144L16003?jcsearch=Fed.%20R.%20Civ.%20P.%2012(b)(1)&amp;summary=yes#jcite">12</a>(b)(1), deeming them insufficiently ripe for
adjudication. We agree with the district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442105" href="#headnote_pq2-dec_442105">[3]</a> Among the requirements for establishing a justiciable case or
controversy under Article III, a dispute must present issues
that are ripe for judicial resolution. "A claim is not ripe for
adjudication if it rests on contingent future events that may
not occur as anticipated, or indeed may not occur at all."
<i>Texas v. United States</i>,
<span CLASS="page_no" data-cite="669 f 3d 1381" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1381" data-primary-citation="669 F.3d 1370">[*1381]</span> 
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X5CD03?jcsearch=523%20us%20296&amp;summary=yes#jcite">523 U.S. 296</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X5CD03?jcsearch=523%20us%20296&amp;summary=yes#jcite">300</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/1?citation=118%20supreme%20court%201257&amp;summary=yes#jcite">118 S.Ct. 1257</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X5CD03?jcsearch=140%20l%20ed%202d%20406&amp;summary=yes#jcite">140 L.Ed.2d 406</a> (1998)
(internal quotations omitted). In the context of patent
infringement actions under &sect; 271(e)(2), we have held that
"<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">Section 271(e)(2)</a> does not encompass `speculative' claims for
infringement." <i>Warner-Lambert</i>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1364</a>.
Regardless what may or may not occur in the future, the
infringement analysis under &sect; 271(e)(2) is limited to
whether the accused infringer's ANDA seeks approval for
activities that would constitute infringement of the asserted
patents. <i>Id.</i> at 1364-65.
<span CLASS="page_no" data-cite="101 uspq 2d 1683" data-cite-type="ReporterOfDecisions" data-cite-pageno="1683" data-primary-citation="101 U.S.P.Q.2d 1675">[**1683]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In view of the foregoing requirements, AstraZeneca's claims
based on presumed future labeling amendments are unripe. As we
have noted, the Act permits generic manufacturers to file ANDAs
directed to a subset of FDA-approved indications and even
provides a mechanism for ANDA applicants to affirmatively carve
out patented indications by submitting Section viii statements.
In this case, Appellees have limited their ANDAs to unpatented
methods for using rosuvastatin calcium, nothing in the record
indicates that the FDA has required Appellees to add further
indications, and we see no reason to presume that the FDA will
do so in the future. In fact, as Appellees point out, the FDA
has tentatively approved several of their ANDAs without issuing
any such requirements. <i>E.g.</i>, J.A. 206-10. Accordingly,
the district court correctly dismissed AstraZeneca's claims as
unripe to the extent that they rely on prospective labeling
amendments for Appellees' generic rosuvastatin calcium because
these claims rest on contingent future events that may never
occur.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the district court erred in part by concluding that
AstraZeneca's failure to state a cognizable &sect; 271(e)(2)
claim defeated its jurisdiction, we nonetheless agree that (1)
AstraZeneca <span CLASS="page_no" data-cite="2012 bl 36466 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> failed to state a &sect; 271(e)(2) claim based on
Appellees' existing ANDA filings, and (2) AstraZeneca's claims
premised on presumed future labeling amendments were not ripe
for adjudication. We therefore affirm the district court's
judgment dismissing the complaint.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> AstraZeneca is also the assignee of U.S. Patent
6,316,460, which discloses and claims particular pharmaceutical
compositions comprising a rosuvastatin compound and a tribasic
phosphate salt. The &prime;460 patent is not involved in this
appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> Individual appellees Aurobindo Pharma, Sun Pharmaceutical
Industries, and Teva Pharmaceuticals USA originally submitted
Paragraph IV certifications regarding the &prime;618 patent but
later amended their ANDAs to replace those certifications with
Section viii statements.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Individual appellees Torrent Pharmaceuticals Ltd. and
Torrent Pharma Inc. were sued separately on July 8, 2010, and
joined in the consolidated action. J.A. 395-404.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> AstraZeneca's complaints against the' individual
appellees are essentially identical; we quote representative
language from AstraZeneca's first amended complaint against
Apotex Corp., filed on April 30, 2010. J.A. 160-69.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> In deciding Appellees' motions to dismiss, the district
court held that it could consider certain documents beyond the
pleadings, including Appellees' ANDA filings, Section viii
statements, and proposed labeling. <i>Astrazeneca</i>,
<cite>2010 WL 5376310</cite>, at *8-9. AstraZeneca complains that the district
court committed legal error by considering such documents
without allowing it to take discovery. However, the district
court was entitled to examine documents "integral to or
explicitly relied upon in the complaint" in evaluating motions
to dismiss. <i>In re Burlington Coat Factory Sec. Litig.</i>,
<a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X4PPCD?jcsearch=114%20f%203d%201410&amp;summary=yes#jcite">114 F.3d 1410</a>, <a href="/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/document/X4PPCD?jcsearch=114%20f%203d%201410&amp;summary=yes#jcite">1426</a> (3d Cir. 1997). The district court
determined, and we agree, that AstraZeneca's complaints
referenced and relied on Appellees' FDA filings, and the
parties do not dispute the authenticity of the documents that
were before the court. We therefore see no error in the
district court's decision to consider these documents.
</p></div>
<!--BBLS DD 1688606146563-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H4KCA003/history">Direct History (2)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H4KCA003/analysis">Case Analysis (12)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1H4KCA003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
11
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1H4KCA003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
1
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Manufacturing</div><div class='facetItemLabel'>Pharmaceuticals</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/b2583b8c3d0acd12e2dfa40cc5832048/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "b2583b8c3d0acd12e2dfa40cc5832048";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYd522cd&previousPageId=&previousActivityInstanceId=ENTITY12ff77&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:33:53-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1H4KCA003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY12ff77&previousPageId=&previousActivityInstanceId=ENTITY2da33f&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:33:44-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1H4KCA003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1H4KCA003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","1718421","3027446"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
